Background: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex. This study investigated the expression of nuclear factor-ĸB (NF-ĸB), mitogen-activated protein (MAP) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate (PDTC), an NF-ĸB inhibitor. Methods: 38 female Wistar rats were injected with gentamicin, 40 mg/kg, twice a day for 9 days, 38 with gentamicin + PDTC, and 28 with 0.15 M NaCl solution. The animals were killed 5 and 30 days after these injections and the kidneys were removed for histological and immunohistochemical studies. The results of the immunohistochemical studies were scored according to the extent of staining. The fractional interstitial area was determined by morphometry. Results: Gentamicin-treated rats presented a transitory increase in plasma creatinine levels. Increased ED-1, MAP kinases and NF-ĸB staining were also observed in the renal cortex from all gentamicin-treated rats compared to control (p < 0.05). The animals killed on day 30 also presented fibrosis in the renal cortex despite the recovery of renal function. Treatment with PDTC reduced the functional and structural changes induced by gentamicin. Conclusions: These data show that inhibition of NF-ĸB activation attenuates tubulointerstitial nephritis induced by gentamicin.

Keywords:
Nuclear factor-ĸB, MAP kinases, Macrophages, Renal fibrosis, Gentamicin-induced acute tubular necrosis
1.
Cronin RE, Henrich WL: Toxic nephropathies; in Brenner BM (ed): The Kidney, ed 6. Philadelphia, Saunders, 2000, pp 1563–1596.
2.
Luft DC: Clinical significance of renal changes engendered by aminoglycosides in man. J Antimicrob Chemother 1984;13(suppl A):23–30.
3.
Cronin RE, Bulger RE, Southern P, Henrich WL: Natural history of aminoglycoside nephrotoxicity in the dog. J Lab Clin Med 1980;95:463–474.
4.
Houghton DC, Lee D, Gilbert DN, Bennett WM: Chronic gentamicin nephrotoxicity. Continued tubular injury with preserved glomerular filtration function. Am J Pathol 1986;123:183–194.
5.
Houghton DC, English J, Bennett WM: Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term ‘subtherapeutic’ gentamicin. J Lab Clin Med 1988;112:694–703.
6.
Geleilete TJ, Melo GC, Costa RS, Volpini RA, Soares TJ, Coimbra TM: Role of myofibroblasts, transforming growth factor-β, endothelin, angiotensin II and fibronectin in the progression of tubulointerstitial nephritis induced by gentamicin. J Nephrol 2002;15:633–642.
7.
Hill CS, Treisman R: Transcriptional regulation by extracellular signals: Mechanisms and specificity. Cell 1995;80:199–211.
8.
Guijarro C, Egido J: Transcription factor-κB (NF-κB) and renal disease. Kidney Int 2001;59:415–424.
9.
Muller DN, Dechend R, Mervaala EMA, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Haller H, Luft FC: NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193–201.
10.
Bokemeyer D, Ostendorf T, Kunter U, Lindemann M, Kramer HJ, Floege J: Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2000;11:232–240.
11.
Bokemeyer D, Sorokin A, Dunn MJ: Multiple intracellular MAP kinase signaling cascades. Kidney Int 1996;49:1187–1198.
12.
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326–1331.
13.
Martindale JL, Holbrook NJ: Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 2002;192:1–15.
14.
Baroni EA, Costa RS, da Silva CGA, Coimbra TM: Heparin treatment reduces glomerular injury in rats with adriamycin-induced nephropathy but does not modify tubulointerstitial damage or the renal production of transforming growth factor-β. Nephron 2000;84:248–257.
15.
Dijkstra CD, Dopp EA, Joling P, Kraal G: The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage subpopulations in the rat recognized by antibodies ED1, ED2 and ED3. Immunology 1985;54:589–599.
16.
Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;57:167–182.
17.
Rangan GK, Wang Y, Tay YC, Harris CH: Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999;56:118–134.
18.
Brophy D, Najarian JS, Kjellstrand CM: Acute tubule necrosis after renal transplantation. Transplantation 1980;29:245–248.
19.
Di Mari JF, Davis R, Safirstein RL: MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol 1999;277:F195–F203.
20.
Mannik EE, Mishra J, Marque J, Clavell M, Miller MJS, Oliver PD: Inhibitors of nuclear factor-κB causes apoptosis in cultured macrophages. Med Inflamm 1997;6:225–232.
21.
Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.
22.
Nikolic-Patterson DJ, Lan HY, Hill PA, Atkins RC: Macrophages in renal injury. Kidney Int 1994;45(suppl):79–82.
23.
Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657–1666.
24.
Cameron JS: Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol 1992;6:292–303.
25.
Vaage J, Lindblad WJ: Production of collagen type I by mouse peritoneal macrophages. J Leukoc Biol 1990;48:274–280.
26.
Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-β induces α-smooth-muscle actin expression in granulation-tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103–111.
27.
Xu SW, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson GD, Black CM, Abraham DJ: Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 2001;116:417–425.
28.
Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464–474.
29.
Border WA, Noble NA: Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998;31(suppl):181–188.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.